Donepezil in the treatment of Alzheimer's disease: Long-term efficacy and safety;Donepezil nella demenza di Alzheimer: Valutazione dell'efficacia a lungo termine

Rivista di Psichiatria

Volumn 35, Issue 6, 2000, Pages 292-295

  Rocca, P ^a   Zanalda, E ^a   Cocuzza, E ^a   Rasetti, R ^a   Rivoira, E ^a   Ravizza, L ^a   Bogetto, F ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Alzheimer's Disease; Cognitive deficit; Donepezil; Efficacy; Safety

Indexed keywords

DONEPEZIL;

ADULT; AGED; ALZHEIMER DISEASE; CLINICAL ARTICLE; COGNITION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MALE; PSYCHIATRIC DIAGNOSIS; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0034500390     PISSN: 00356484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. The cholinergic hypothesis of Alzheimer's disease: A review of progress
2. Evaluation of dementia
3. DSM-IV diagnostic and statistical manual of mental disorder, fourth edition
4. Cholinesterase inhibitors: A new class of psychotropic compounds
5. The cholinergic deficit in Alzheimer's disease
6. New therapeutic approaches to cognitive impairment
7. Cholinesterase inhibitors: A therapeutic strategy for Alzheimer disease
8. The efficacy and safety of Donepezil in patients with Alzheimer's disease: Results of a multicenter, randomized, double-blind, placebo-controlled trial
9. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's Disease: An interim analysis of the results of a US multicentre open label extension study
10. A 24 week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
11. Results from a multinational trial. The effects donepezil in Alzheimer's disease
12. A large-scale trial of donepezil in the treatment of Alzheimer's Disease: Concomitant medications and the effects on heart rate
13. An evaluation of the long-term efficacy of donepezil in patients from a Phase III clinical extension trial
14. The spectrum of behavioral responses to cholinesterase Inhibitor therapy in Alzheimer disease